Dr. Fabio Massaiti Iwamoto, MD

Dr. Iwamoto practices at Columbia University Irving Medical Center in New York, New York.

Dr. Iwamoto's NPI, 1053623934, was assigned on July 8, 2010. Dr. Iwamoto graduated from Federal University of Parana Faculty of Medicine in 1999. Dr. Iwamoto's New York license number on file is 264009.

Dr. Iwamoto's primary practice is Columbia University Irving Medical Center, at 622 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 297-4255.

Dr. Iwamoto's primary practice is Columbia University Irving Medical Center in New York, New York. Dr. Iwamoto is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Iwamoto to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Iwamoto practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Iwamoto's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Iwamoto is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Iwamoto's licenses on file in 5 states: New York, Florida, Connecticut, New Jersey and Pennsylvania.

Dmand AI lists mobility impairment among the conditions Dr. Iwamoto treats.

CMS data shows 938 Medicare services from Dr. Iwamoto across 5 procedure codes in 2024, for 114 Medicare patients. Medicare paid $80,502 for them. Every service was in an office.

CMS counts 114 Medicare patients who saw Dr. Iwamoto in 2024. The largest group is 65 to 74, with 56 patients. 68% of them have high cholesterol, and 61% have high blood pressure. 23% are also on Medicaid. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Iwamoto's median patient age at 50, with 46% women.

In 2024, Dr. Iwamoto wrote 73 Medicare Part D claims for 28 patients. 93% of them were for generic drugs. CMS names the drug for 45 of them, across 3 drugs with 11 or more claims each, at $1,282 in total drug cost. In 2021, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Iwamoto for performance year 2024, reported through an alternative payment model (APM). Dr. Iwamoto accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Iwamoto as offering telehealth.

Dmand AI links 103 papers to Dr. Iwamoto, published from 2007 to 2025. 2016 was the busiest year, with 6. The most frequent topics are Brain Neoplasms, Glioblastoma and Glioma. Dr. Iwamoto has published most often in J Neurooncol. Dr. Iwamoto's most frequent co-authors are Jeffrey N. Bruce, MD, Michael Brian Sisti, MD and Howard A. Fine, MD.

Dmand AI links Dr. Iwamoto to 12 clinical trials, 4 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Glioblastoma, Astrocytoma and Glioma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 90 general payments to Dr. Iwamoto from 9 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 34% of the total. Novocure Inc. paid the most, $28,425. It also lists 1 research payment totaling $97 in 2016.

Dr. Iwamoto graduated from Federal University of Parana Faculty of Medicine in 1999. Dr. Iwamoto is a member of ASCO.

Dr. Iwamoto is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.